Katugampola S D, Maguire J J, Kuc R E, Wiley K E, Davenport A P
University of Cambridge, Centre for Clinical Investigation, Addenbrooke's Hospital, UK.
Can J Physiol Pharmacol. 2002 May;80(5):369-74. doi: 10.1139/y02-029.
Using novel synthetic radioligands, we have discovered receptors for the recently paired apelin (APJ orphan receptor), ghrelin (GHS orphan receptor), and urotensin II (orphan GPR14) in the human cardiovascular system and determined their anatomical localisation. In addition, we have established functional vasoactive properties for these three peptides as potential vasoconstrictor/vasodilator mediators and provided evidence for alteration of receptor density in cardiovascular disease. We find that receptors for apelin, ghrelin, and urotensin II are widely distributed in human cardiovascular tissue, suggesting perhaps vasoactive roles for these peptides in human vascular physiology and a potential role in pathophysiology. Apelin and urotensin II are potent vasoconstrictors with low efficacy, consistent with their low receptor density. Ghrelin receptor density was increased (approximately three- to fourfold) with atherosclerosis of coronary artery disease and accelerated atherosclerosis of saphenous vein grafts, compared with normal vessels, highlighting a potentially beneficial role for this novel vasodilator peptide in human vascular disease. Our approach has demonstrated one successful strategy for translating genetic information encoding recently paired orphan receptor ligands into discovery of function. This study has the advantage of focussing on the actual disease processes, which allow the more precise identification of novel therapeutic targets.
我们使用新型合成放射性配体,在人体心血管系统中发现了近期配对的apelin(APJ孤儿受体)、胃饥饿素(GHS孤儿受体)和尾加压素II(孤儿GPR14)的受体,并确定了它们的解剖定位。此外,我们确定了这三种肽作为潜在血管收缩剂/血管舒张剂介质的血管活性特性,并提供了心血管疾病中受体密度改变的证据。我们发现,apelin、胃饥饿素和尾加压素II的受体广泛分布于人体心血管组织中,这表明这些肽可能在人体血管生理中发挥血管活性作用,并在病理生理学中具有潜在作用。Apelin和尾加压素II是效力较低的强效血管收缩剂,这与其低受体密度一致。与正常血管相比,冠状动脉疾病的动脉粥样硬化和大隐静脉移植物的加速动脉粥样硬化使胃饥饿素受体密度增加(约三到四倍),这突出了这种新型血管舒张肽在人类血管疾病中可能具有的有益作用。我们的方法展示了一种将编码近期配对孤儿受体配体的遗传信息转化为功能发现的成功策略。这项研究的优势在于专注于实际疾病过程,从而能够更精确地识别新型治疗靶点。